




RealRate

PHARMACEUTICAL 2023

Verastem Inc.
Rank 288 of 446





RealRate

PHARMACEUTICAL 2023

Verastem Inc.
Rank 288 of 446



The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Verastem Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 11%, being 32% points below the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 92,870 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 21,663 |
| Liabilities, Non-Current | 1,470 |
| Other Assets | 2,088 |
| Other Compr. Net Income | -34 |
| Other Expenses | 2,137 |
| Other Liabilities | 24,526 |
| Other Net Income | 1,262 |
| Other Revenues | 2,596 |
| Property and Equipment | 92 |
| Research and Development | 50,558 |
| Selling, General and Administrative Expense | 24,975 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 95,050 |
| Liabilities | 47,659 |
| Expenses | 77,670 |
| Revenues | 2,596 |
| Stockholders Equity | 47,391 |
| Net Income | -73,812 |
| Comprehensive Net Income | -73,829 |
| Economic Capital Ratio | 11% |